Equities Analysts Set Expectations for HeartBeam Q3 Earnings

HeartBeam, Inc. (NASDAQ:BEAT) – Research analysts at HC Wainwright boosted their Q3 2026 earnings per share (EPS) estimates for shares of HeartBeam in a research report issued on Tuesday, September 22nd. HC Wainwright analyst Y. Chen now forecasts that the medical research company will earn ($0.09) per share for the quarter, up from their prior forecast of ($0.10). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for HeartBeam’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for HeartBeam’s Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.37) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.06) EPS, Q4 2027 earnings at ($0.05) EPS and FY2027 earnings at ($0.24) EPS.

HeartBeam (NASDAQ:BEAT) last announced its quarterly earnings data on Thursday, August 13th. The medical research company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01).

Several other equities research analysts have also recently issued reports on BEAT. Maxim Group started coverage on shares of HeartBeam in a research report on Tuesday, July 14th. They issued a “buy” rating and a $2.00 target price on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of HeartBeam in a report on Thursday, July 2nd. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $4.00.

HeartBeam Trading Down 10.3%

NASDAQ BEAT opened at $0.39 on Thursday. The business’s 50-day moving average price is $0.49 and its 200 day moving average price is $0.78. HeartBeam has a twelve month low of $0.39 and a twelve month high of $4.00. The company has a market capitalization of $21.91 million, a PE ratio of -0.76 and a beta of -0.80.

Institutional Trading of HeartBeam

Several large investors have recently bought and sold shares of the company. Sigma Planning Corp lifted its position in shares of HeartBeam by 86.9% during the second quarter. Sigma Planning Corp now owns 247,700 shares of the medical research company’s stock worth $186,000 after purchasing an additional 115,150 shares in the last quarter. Beacon Pointe Advisors LLC acquired a new stake in HeartBeam during the 2nd quarter valued at $185,000. Finally, BlackRock Inc. purchased a new stake in HeartBeam during the 2nd quarter worth $741,000. Institutional investors and hedge funds own 7.77% of the company’s stock.

More HeartBeam News

Here are the key news stories impacting HeartBeam this week:

• Positive Sentiment: HC Wainwright raised multiple earnings estimates. The analyst increased its forecasts for Q3 and Q4 2026, all four quarters of 2027, FY2026, and FY2027. The FY2027 loss estimate improved to $(0.24) per share from $(0.31), while the FY2026 loss estimate improved to $(0.37) from $(0.41). These revisions suggest expectations for slower cash burn or improving operating performance. HeartBeam earnings estimates
• Neutral Sentiment: HeartBeam is reportedly shifting focus toward heart-attack detection technology. The strategic emphasis could improve the company’s commercial opportunity if the technology gains clinical or regulatory traction, but the available report provides no new approval, partnership, or revenue details. HeartBeam shifts focus to heart-attack detection technology
• Negative Sentiment: HC Wainwright downgraded BEAT from “Buy” to “Neutral.” The downgrade is a more immediate negative catalyst and signals reduced conviction in the stock’s risk-reward profile. It is especially significant because HeartBeam continues to report losses, with the latest quarterly EPS missing expectations and the consensus full-year forecast still calling for a $(0.41) loss per share. HeartBeam stock rating lowered by HC Wainwright

About HeartBeam

HeartBeam, Inc develops wearable and digital cardiac-monitoring technologies designed to help detect and evaluate heart conditions outside traditional clinical settings. The company’s platform is intended to capture electrocardiogram (ECG) data in a portable, cable-free format and transmit that information through a connected mobile device.

HeartBeam’s technology is based on three-dimensional vector ECG recordings, which are designed to provide electrical views of the heart from multiple directions rather than relying solely on a conventional single-lead wearable reading.